The US Food and Drug Administration (FDA) has approved the implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator devices that feature Bluetooth connectivity and continuous remote monitoring, both developed by Abbott. The new system pairs with a smartphone app, my MerlinPulse, which is compatible with both iOS and Android. The app helps streamline communication between patients and their doctors and helps patients take an active role in their healthcare by allowing them to access data, device performance, and transmission history. Moreover, physicians can continuously monitor their patients remotely with the app, enabling them to identify asymptomatic episodes and to intervene early if necessary.